Showing 751-760 of 2293 results for "".
- New Social Networking Platform for the Multiple Sclerosis Communityhttps://practicalneurology.com/news/new-social-networking-platform-for-the-multiple-sclerosis-community/2469254/A new free anonymous AI-powered social networking and navigation platform, BelongMS (Belong.Life, New York, NY), has been launched for individuals with multiple sclerosis (MS), caregivers, and healthcare professionals. The app can be downloaded for Android and iOS. The new app follows t
- Registry Database for COVID-19 in People With Multiple Sclerosis Createdhttps://practicalneurology.com/news/registry-database-for-covid-19-in-people-with-multiple-sclerosis-created/2469229/The Consortium of Multiple Sclerosis Centers (CMSC) and the National Multiple Sclerosis Society have worked together to create COViMS, a new North American database to capture COVID-19 infections in individuals with multiple sclerosis (MS) and related diseases. This joint effort will capture info
- Nanocatalytic Gold Therapy Well Tolerated in Clinical Trial for Multiple Sclerosishttps://practicalneurology.com/news/nanocatalytic-gold-therapy-well-tolerated-in-clinical-trial-for-multiple-sclerosis/2469174/Preliminary data from the randomized placebo-controlled phase 2 VISIONARY-MS trial (NCT03536559) of nanocatalytic gold therapy (CNM-Au8; Clene Nanomedicine, Salt Lake City, UT) suggest the drug is well tolerated. Preliminary blinded da
- Update to MRI Protocols for Multiple Sclerosis from the Consortium of Multiple Sclerosis Centershttps://practicalneurology.com/news/update-to-mri-protocols-for-multiple-sclerosis-from-the-consortium-of-multiple-sclerosis-centers/2469172/The Consortium of Multiple Sclerosis Centers (CMSC) has revised MRI protocols for multiple sclerosis (MS). The updated Standardized Brain MRI Protocol includes • Mandatory axial FLAIR, sagittal FLAIR, and axial T2 imaging • Use of
- Machine Learning Models to Aid Early Accurate Diagnosis of Multiple Sclerosishttps://practicalneurology.com/news/machine-learning-models-to-aid-early-accurate-diagnosis-of-multiple-sclerosis/2469171/Machine learning models performed with sensitivity and specificity for distinguishing between the brains of people with and without multiple sclerosis (MS). These models were constructed using a medical device software program that computes volumetric brain measurement from MRIs (NeuroQuant 3.0;
- Clinical Trial to Compare Stem Cell Treatment to High-Efficacy Biologics for Treatment of Relapsing Multiple Sclerosishttps://practicalneurology.com/news/clinical-trial-to-compare-stem-cell-treatment-to-high-efficacy-biologics-for-treatment-of-relapsing-multiple-sclerosis/2469126/A clinical trial will test autologous hematopoietic stem cell treatment (AHSCT) against the best available biologic therapies for severe forms of relapsing multiple sclerosis (MS). The trial will compare the safety, efficacy, and cost-effectiveness of the 2 therapeutic approaches and has begun en
- Generic Fingolimod for Relapsing Forms of Multiple Sclerosis Approved by the FDAhttps://practicalneurology.com/news/generic-fingolimod-for-relapsing-forms-of-multiple-sclerosis-approved-by-the-fda/2469094/The Food and Drug Administration (FDA) has approved 3 applications for the first generics of fingolimod (Gilenya; Novartis AG, Basel, Switzerland) for treating relapsing forms of multiple sclerosis (MS) in adult patients. Fingolimod is a sphingosine 1-phosphate receptor modulator indica
- Advancement in Multiple Sclerosis and The Effect on Pregnancyhttps://practicalneurology.com/news/advancement-in-multiple-sclerosis-and-the-effect-on-pregnancy/2469078/On a global level, there is a concerning gap between the results of clinical trials and regulators' approval of advanced therapies, leaving some individuals with multiple sclerosis (MS) without access to the most effective options. Therapeutic lags have resulted in entire regions where indivi
- Partnership Between Community and Academic Healthcare Can Improve Standardization of Imaging Protocols for Multiple Sclerosishttps://practicalneurology.com/news/partnership-between-community-and-academic-healthcare-can-improve-standardization-of-imaging-protocols-for-multiple-sclerosis/2468813/Guidelines exist for standardized MRI for monitoring disease activity in patients with multiple sclerosis (MS) and enhance quality of care for patients as well as creating the opportunity to have standardized data for research. Outside of tertiary care centers, however, these protocols often are
- Rates of Initiating Disease-Modifying Treatment for Multiple Sclerosis Remain Lowhttps://practicalneurology.com/news/rates-of-initiating-disease-modifying-treatment-for-multiple-sclerosis-remain-low/2468819/Research suggests that as many as 43% of patients with multiple sclerosis (MS) do not take a disease-modifying treatment (DMT) for the first 2 years of their diagnosis or longer. In a retrospective claims analysis using the IQVIA adjudicated claims database from June 2010 to June, 2017.